Anesthesia & Clinical Research
Open Access

Department of Pulmonary and Critical Care Medicine, Max Super Specialty Hospital, Mohali, Punjab, India

Publications

• Research   
  Survival and Outcomes of Tocilizumab use in Severe and Critically-ill COVID-19 Patients not Responding to Steroids
  Author(s): Shiraz Assu*, Deepak Bhasin, Supriya Sampley, Harpal Singh, Gurleen Kaur and Kavita Sekhri
  
  Background: Outcomes are poorest in severe and critical COVID-19 pneumonia. We share our experience with the use of interleukin-6 receptor inhibitor, tocilizumab in the above patient group when given along with steroids. Methods: In this retrospective observational study, all severe and critical COVID-19 patients, who got admitted to the intensive care unit and subsequently received tocilizumab were included. Patients who worsened clinically or had no change in oxygen requirement even after 24 hrs of receiving intravenous methylprednisolone at a dose of 1-2 mg/kg/day had received a maximum total dose of 800 mg of intravenous tocilizumab. The day 28 all-cause mortality and progression to mechanical ventilation were the primary outcome measures. Clinical improvement, trends in oxygen requirements and inflammatory markers along with secondary inf.. View More»
  DOI: 10.35248/2155-6148.22.13.1057

  Abstract HTML PDF